Fractyl Health, Inc. has announced the entry into a significant underwriting agreement with Ladenburg Thalmann & Co. Inc. This agreement pertains to the underwritten offering, issuance, and sale of 19,047,619 shares of the company's common stock, alongside accompanying Tranche A and Tranche B Warrants, all priced at a combined offering of $1.05 per share with accompanying warrants. The net proceeds from this offering will be utilized to bolster Fractyl Health's Revita and Rejuva pipeline programs and for general corporate purposes. Additionally, Fractyl Health has committed to holding a special stockholder meeting to seek approval for the Tranche B Warrants within 60 days of closing the offering, with strong backing from the company's board and key stakeholders.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.